Treatments for weight management and metabolic disease

Response Pharmaceuticals is focused on developing innovative solutions for weight management and metabolic health, particularly through its drug candidate RDX-002. This novel small molecule acts as an iMTP inhibitor and is currently being evaluated in a Phase 2 clinical study for patients who are discontinuing GLP-1 agonists. The company has made significant progress in its clinical trials, including achieving primary endpoints in a Phase 1b trial aimed at addressing antipsychotic-induced weight gain (AIWG). This highlights Response Pharmaceuticals' commitment to addressing critical health issues associated with weight management.

The company's research and development efforts are underscored by its successful completion of Phase 1B clinical trials for RDX-002, which demonstrates the potential efficacy of this treatment in managing weight gain linked to antipsychotic medications. Additionally, Response Pharmaceuticals has secured funding through a Series A financing round, which will support its ongoing clinical studies and further development of its product pipeline. Overall, Response Pharmaceuticals is positioned to make a significant impact in the field of metabolic health with its targeted therapeutic approaches.

United States

Response Pharmaceuticals, Inc, is a clinical-stage therapeutic development company focused on developing treatments for weight management and metabolic disease. Our initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments.

Response Pharmaceuticals

Company Details